Inflammatory Bowel Disease Market by Distribution Channel, Type and Geography- Forecast and Analysis 2023-2027

Published: Oct 2023 Pages: 165 SKU: IRTNTR75652

Inflammatory Bowel Disease Market Forecast 2023-2027

The inflammatory bowel disease market size is estimated to grow by USD 7.68 billion at a CAGR of 5.77% between 2023 and 2027. The increasing incidence of IBD worldwide is leading to a greater demand for effective therapies to manage the condition. The growing preference for biologics and targeted therapies, which offer more personalized treatment options with potentially fewer side effects, is driving market growth. Additionally, increasing awareness of IBD, its symptoms, and available treatments is leading to earlier diagnosis and treatment, further driving market demand. Furthermore, advancements in biological therapies and targeted treatments are expanding the treatment options available for IBD patients, driving market growth. The emphasis on improving the quality of life for IBD patients and reducing the burden of the disease is also fueling research and development efforts in the field, leading to innovative therapies and treatment approaches.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

This market report extensively covers market segmentation by distribution channel (offline and online), type (Crohn's disease and ulcerative colitis), and geography (North America, Europe, Asia, and Rest of the World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

By Distribution Channel

The market share growth by the offline segment will be significant during the forecast period. The offline channel is a crucial element in the global IBD market. This segment comprises the distribution of IBD therapeutics through traditional brick-and-mortar pharmacies and drugstores. Although the global IBD market has seen an increase in penetration of Internet distribution channels, due to their easy availability and ease of use, there is still a considerable influence on the market from offline channels.

Get a glance at the market contribution of various segments View the PDF Sample

The offline segment showed a gradual increase in the market share of USD 16.67 billion in 2017. Consumers often prefer to purchase drugs in brick-and-mortar stores due to the assurance of immediate availability and face-to-face interactions with pharmacists. The offline channel benefits from this preference, as it allows both established and emerging pharmaceutical companies to reach a wider consumer base. 

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The increasing incidence and prevalence of chronic gastrointestinal diseases and growing healthcare expenditure are driving the growth of the market in North America. Furthermore, factors such as the growing focus of pharmaceutical and biotechnology companies on R&D to develop novel drugs for IBD and the presence of global and regional companies are also driving the market growth in the region during the forecast period.

Market Dynamics and Customer Landscape

The market is witnessing significant advancements, with a focus on innovative therapies and enhanced diagnostic approaches. Key players like Allergan, Ferring Pharmaceuticals, and Lilly are investing in research and development to develop biological drugs and JAK inhibitors such as Cimzia and Jyseleca. These advancements aim to address the complex nature of IBD, including Crohn's disease, through targeted therapies. Additionally, collaborations with organizations like the Crohn's & Colitis Foundation of America are driving clinical trials and providing better insights into the environmental triggers and genetic predispositions of IBD, benefiting healthcare systems and professionals globally. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The increasing demand for biologics and targeted therapies is notably driving the market growth. Surgery is often used to alleviate symptoms in patients with ulcerative colitis and Crohn's disease. However, individuals with Crohn's disease are at a higher risk of developing colon cancer, so surgical techniques may also be employed to reduce this risk. Gastrointestinal surgeries for IBD can carry risks, which can be a concern for patients considering their treatment options. Advances in surgical techniques and medications like biological drugs such as Cimzia have helped improve outcomes and reduce risks, but patients need to discuss all potential risks and benefits with their healthcare providers. Clinical trials and research efforts, supported by organizations like the Crohn's & Colitis Foundation of America, play a crucial role in advancing our understanding and treatment of Crohn's disease and ulcerative colitis. Additionally, companies like Allergan and CytoReason are involved in developing innovative solutions for IBD.

Due to the potential side effects and risks of surgery, pharmaceutical and biopharmaceutical companies are focusing on developing biologics and advanced targeted therapies for gastrointestinal diseases like IBD. These therapies target specific proteins, tissues, or genes responsible for gastrointestinal diseases. The shift towards using biologics and biosimilars as alternatives to traditional IBD therapies is expected to drive the growth of the global market in the forecast period.

Significant Market Trends

The new launches of IBD therapeutics are a primary trend in the inflammatory bowel disease market. companies in the market are focusing on the development of new therapeutics, such as small molecules and biologics, for the treatment of various IBDs. The development of advanced treatments for inflammatory bowel disease has been supported by increasing research and development spending from pharmaceutical and biopharma companies, as well as new product launches.

HUMIRA is the first subcutaneous biologic therapeutic option for patients with moderately to severely active ulcerative colitis aged five and above. Adalimumab-flip, a TNF inhibitor, was given the all-clear by the US FDA in July 2020 to be used in the treatment of adult patients with mildly to moderately active Crohn's disease or ulcerative colitis who have not responded well to traditional therapy. Such developments and an increase in the number of new launches and product approvals of therapeutics for IBD are expected to drive the growth of the global IBD market during the forecast period.

Major Market Challenge

The adverse effects associated with drugs used for treating IBD is a major challenge in the market. Corticosteroids are one of the most commonly prescribed medications for Crohn's disease and ulcerative colitis. Although corticosteroids are used to reduce inflammation in the digestive tract, they should not be used in the long term. Steroids interfere with the formation of a protective mucous layer inside the stomach.

Moreover,  factors such as the nature of the medicine, its content, and duration of use are crucial to the side effects of IBD therapies. In general, it is very easy to treat side effects resulting from the use of these medicines as they often last only a few days. However, the increased chances of developing adverse reactions due to the long-term intake of certain IBD therapeutics may reduce the adoption of such products, which will hamper the growth of the global IBD market during the forecast period.

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Inflammatory Bowel Disease Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AstraZeneca - The company offers inflammatory bowel disease solutions such as CAR-T therapy.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • Bausch Health Co. Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biocon Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Distribution Channel Outlook 
    • Offline
    • Online
  • Type Outlook 
    • Crohn's disease
    • Ulcerative colitis
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World
      • Australia
      • Brazil
      • Saudi Arabia

Market Analyst Overview

The market is driven by advancements in diagnostic techniques and therapeutic drugs, offering enhanced options for patients. The disease burden of IBD, particularly the Crohn's disease segment, underscores the need for improved access to healthcare systems and services. Biologic drugs like Remicade, Entyvio, Simponi, and Skyrizi target the immune system disruption characteristic of IBD, providing relief for patients. Emerging treatments such as IL inhibitors, Janus kinase inhibitors, and toll-like receptor agonists offer further hope for managing the disease. With technological advancements and the rise of telemedicine, healthcare professionals can now better manage IBD, ensuring timely diagnosis and treatment.

The market has seen significant advancements in diagnostic and therapeutic drugs, leading to improved disease detection rates and enhanced therapy. Understanding the disease pathophysiology has been key in developing targeted treatments, with drugs categorized under various Drug Classes such as TNF inhibitors like Remicade and Humira. Emerging treatments like Lilly's Mirikizumab and Takeda's Rinvoq offer new options for patients. The availability of these drugs through different Routes of Administration, including injectable and oral, has made them more accessible through various healthcare channels such as hospital pharmacies, online pharmacies, and retail pharmacies. This has significantly improved the quality of care for IBD patients, particularly in industrialized countries.

Market Scope

Report Coverage

Details

Page number

165

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.77%

Market growth 2023-2027

USD 7.68 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

4.92

Regional analysis

North America, Europe, Asia, and Rest of the World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Canada, UK, China, and India

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., Bausch Health Co. Inc., Baxter International Inc., Bayer AG, Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Services Inc.

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global inflammatory bowel disease market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global inflammatory bowel disease market 2017 - 2021 ($ million)
    • 4.2 Distribution Channel Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Offline - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%)
    • 6.4 Online - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Distribution Channel
      • Exhibit 42: Market opportunity by Distribution Channel ($ million)
      • Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 44: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 45: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 46: Chart on Comparison by Type
      • Exhibit 47: Data Table on Comparison by Type
    • 7.3 Crohn disease - Market size and forecast 2022-2027
      • Exhibit 48: Chart on Crohn disease - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Data Table on Crohn disease - Market size and forecast 2022-2027 ($ million)
      • Exhibit 50: Chart on Crohn disease - Year-over-year growth 2022-2027 (%)
      • Exhibit 51: Data Table on Crohn disease - Year-over-year growth 2022-2027 (%)
    • 7.4 Ulcerative colitis - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Ulcerative colitis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on Ulcerative colitis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on Ulcerative colitis - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Ulcerative colitis - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 56: Market opportunity by Type ($ million)
      • Exhibit 57: Data Table on Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 59: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 60: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 61: Chart on Geographic comparison
      • Exhibit 62: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 China - Market size and forecast 2022-2027
      • Exhibit 83: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 India - Market size and forecast 2022-2027
      • Exhibit 91: Chart on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on India - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on India - Year-over-year growth 2022-2027 (%)
    • 9.11 Canada - Market size and forecast 2022-2027
      • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 99: Market opportunity by geography ($ million)
      • Exhibit 100: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 101: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 103: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 104: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 105: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 106: Matrix on vendor position and classification
            • 12.3 AstraZeneca
              • Exhibit 107: AstraZeneca - Overview
              • Exhibit 108: AstraZeneca - Product / Service
              • Exhibit 109: AstraZeneca - Key news
              • Exhibit 110: AstraZeneca - Key offerings
            • 12.4 Aurobindo Pharma Ltd.
              • Exhibit 111: Aurobindo Pharma Ltd. - Overview
              • Exhibit 112: Aurobindo Pharma Ltd. - Product / Service
              • Exhibit 113: Aurobindo Pharma Ltd. - Key offerings
            • 12.5 Baxter International Inc.
              • Exhibit 114: Baxter International Inc. - Overview
              • Exhibit 115: Baxter International Inc. - Business segments
              • Exhibit 116: Baxter International Inc. - Key news
              • Exhibit 117: Baxter International Inc. - Key offerings
              • Exhibit 118: Baxter International Inc. - Segment focus
            • 12.6 Bayer AG
              • Exhibit 119: Bayer AG - Overview
              • Exhibit 120: Bayer AG - Business segments
              • Exhibit 121: Bayer AG - Key news
              • Exhibit 122: Bayer AG - Key offerings
              • Exhibit 123: Bayer AG - Segment focus
            • 12.7 Eli Lilly and Co.
              • Exhibit 124: Eli Lilly and Co. - Overview
              • Exhibit 125: Eli Lilly and Co. - Product / Service
              • Exhibit 126: Eli Lilly and Co. - Key news
              • Exhibit 127: Eli Lilly and Co. - Key offerings
            • 12.8 F. Hoffmann La Roche Ltd.
              • Exhibit 128: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 129: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 130: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 131: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 132: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 133: GlaxoSmithKline Plc - Overview
              • Exhibit 134: GlaxoSmithKline Plc - Business segments
              • Exhibit 135: GlaxoSmithKline Plc - Key news
              • Exhibit 136: GlaxoSmithKline Plc - Key offerings
              • Exhibit 137: GlaxoSmithKline Plc - Segment focus
            • 12.10 Johnson and Johnson Services Inc.
              • Exhibit 138: Johnson and Johnson Services Inc. - Overview
              • Exhibit 139: Johnson and Johnson Services Inc. - Business segments
              • Exhibit 140: Johnson and Johnson Services Inc. - Key news
              • Exhibit 141: Johnson and Johnson Services Inc. - Key offerings
              • Exhibit 142: Johnson and Johnson Services Inc. - Segment focus
            • 12.11 Merck and Co. Inc.
              • Exhibit 143: Merck and Co. Inc. - Overview
              • Exhibit 144: Merck and Co. Inc. - Business segments
              • Exhibit 145: Merck and Co. Inc. - Key news
              • Exhibit 146: Merck and Co. Inc. - Key offerings
              • Exhibit 147: Merck and Co. Inc. - Segment focus
            • 12.12 Novartis AG
              • Exhibit 148: Novartis AG - Overview
              • Exhibit 149: Novartis AG - Business segments
              • Exhibit 150: Novartis AG - Key offerings
              • Exhibit 151: Novartis AG - Segment focus
            • 12.13 Pfizer Inc.
              • Exhibit 152: Pfizer Inc. - Overview
              • Exhibit 153: Pfizer Inc. - Product / Service
              • Exhibit 154: Pfizer Inc. - Key news
              • Exhibit 155: Pfizer Inc. - Key offerings
            • 12.14 Sanofi
              • Exhibit 156: Sanofi - Overview
              • Exhibit 157: Sanofi - Business segments
              • Exhibit 158: Sanofi - Key news
              • Exhibit 159: Sanofi - Key offerings
              • Exhibit 160: Sanofi - Segment focus
            • 12.15 Sun Pharmaceutical Industries Ltd.
              • Exhibit 161: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 162: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 163: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 164: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 165: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 166: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 168: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 169: Viatris Inc. - Overview
              • Exhibit 170: Viatris Inc. - Business segments
              • Exhibit 171: Viatris Inc. - Key news
              • Exhibit 172: Viatris Inc. - Key offerings
              • Exhibit 173: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 174: Inclusions checklist
                • Exhibit 175: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 176: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 177: Research methodology
                • Exhibit 178: Validation techniques employed for market sizing
                • Exhibit 179: Information sources
              • 13.5 List of abbreviations
                • Exhibit 180: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              inflammatory bowel disease market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis